RE: "Kim had monster silk, then monster hybrid, there is no reason other than incompetence for why there is ZERO COMMERCIALIZATION progress. No lab, no suitors, no "deals" just still in "laboratory production"
To use your own words against you:
"NO PROOF OF THIS WHATSOEVER
.... [I deleted the personal attack part]
What you need to do is support your claims WITH EVIDENCE. "
That is: you have "no proof whatsoever" that there is zero commercialization progress. You have no way of knowing exactly what's been going on in the lab or what progress has been made. Those with a background can make reasonable guesses and inferences (which are still obviously conjectures) but you obviously have no background in biotechnology whatsoever. I can say that with confidence because if you had the least bit, you would understand that the pace of research is inherently uncertain, problems arise and have to be solved and not all progress gets reported to shareholders and for very good reasons. One of the biggest is that those with backgrounds as limited as yours apparently is and tendencies like yours to assume the worst would almost certainly react negatively to any PR that "we had a problem and it has been solved". (name me ONE example of ANY biotech that has issued such a Pr!)
In addition you very clearly do not understand the steps necessary (you didn't, for example, know about the need to make the GMed worms homozygous until I pointed it out) so obviously you cannot possibly know what steps will need to be taking place behind the scenes.
IMHO the thing that is really causing you such difficulty is your apparent unwillingness to acknowledge that there ARE things about this that you don't understand. If you did so you would not be so prone to IMHO jump to conclusions based on failure for events to meet your expectations. Has it never occurred to you that perhaps your expectations are unrealistic?
"The single biggest limitation on the successful application of knowledge is the failure to appreciate its limitations" JDB
AI
Market Data 
Markets 
